Trials / Terminated
TerminatedNCT00174382
Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia
An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 149 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. The effects of donepezil on executive functioning, behavior, general cognition, ADLs and global functioning will be assessed.
Detailed description
The trial was terminated on October 15, 2007 due to difficulties in recruiting the subjects. There were no safety or efficacy concerns regarding the study medication in the decision to terminate the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donepezil | donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2005-09-15
- Last updated
- 2015-03-24
- Results posted
- 2009-06-12
Locations
30 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00174382. Inclusion in this directory is not an endorsement.